News Quantified

EDIT – editas medicine, inc. (US:NASDAQ)

Editas Medicine (NASDAQ:EDIT) was upgraded by analysts at Chardan Capital from a "hold" rating to a "strong-buy" rating.

11/10

07:11 am

edit

Medium

Editas Medicine Announces Third Quarter 2025 Results and Business Updates [Yahoo! Finance]

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Editas Medicine (NASDAQ:EDIT) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}